TY - JOUR
T1 - Two-dimensional transcriptome profiling
T2 - Identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens
AU - Li, Hai Ri
AU - Wang-Rodriguez, Jessica
AU - Nair, T. Murlidharan
AU - Yeakley, Joanne M.
AU - Kwon, Young Soo
AU - Bibikova, Marina
AU - Zheng, Christina
AU - Zhou, Lixin
AU - Zhang, Kui
AU - Downs, Tracy
AU - Fu, Xiang Dong
AU - Fan, Jian Bing
PY - 2006/4/15
Y1 - 2006/4/15
N2 - The expression of specific mRNA isoforms may uniquely reflect the biological state of a cell because it reflects the integrated outcome of both transcriptional and posttranscriptional regulation. In this study, we constructed a splicing array to examine ∼1,500 mRNA isoforms from a panel of genes previously implicated in prostate cancer and identified a large number of cell type-specific mRNA isoforms. We also developed a novel "two-dimensional" profiling strategy to simultaneously quantify changes in splicing and transcript abundance; the results revealed extensive covariation between transcription and splicing in prostate cancer cells. Taking advantage of the ability of our technology to analyze RNA from formalin-fixed, paraffin-embedded tissues, we derived a specific set of mRNA isoform biomarkers for prostate cancer using independent panels of tissue samples for feature selection and cross-analysis. A number of cancer-specific splicing switch events were further validated by laser capture microdissection. Quantitative changes in transcription/RNA stability and qualitative differences in splicing ratio may thus be combined to characterize tumorigenic programs and signature mRNA isoforms may serve as unique biomarkers for tumor diagnosis and prognosis.
AB - The expression of specific mRNA isoforms may uniquely reflect the biological state of a cell because it reflects the integrated outcome of both transcriptional and posttranscriptional regulation. In this study, we constructed a splicing array to examine ∼1,500 mRNA isoforms from a panel of genes previously implicated in prostate cancer and identified a large number of cell type-specific mRNA isoforms. We also developed a novel "two-dimensional" profiling strategy to simultaneously quantify changes in splicing and transcript abundance; the results revealed extensive covariation between transcription and splicing in prostate cancer cells. Taking advantage of the ability of our technology to analyze RNA from formalin-fixed, paraffin-embedded tissues, we derived a specific set of mRNA isoform biomarkers for prostate cancer using independent panels of tissue samples for feature selection and cross-analysis. A number of cancer-specific splicing switch events were further validated by laser capture microdissection. Quantitative changes in transcription/RNA stability and qualitative differences in splicing ratio may thus be combined to characterize tumorigenic programs and signature mRNA isoforms may serve as unique biomarkers for tumor diagnosis and prognosis.
UR - http://www.scopus.com/inward/record.url?scp=33646240135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646240135&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-4264
DO - 10.1158/0008-5472.CAN-05-4264
M3 - Article
C2 - 16618727
AN - SCOPUS:33646240135
SN - 0008-5472
VL - 66
SP - 4079
EP - 4088
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -